KaliVir Immunotherapeutics develops oncolytic viral immunotherapy programs utilizing its Novel Vaccinia Enhanced Template (VET) platform to target and destroy cancer cells. This approach addresses the need for effective cancer treatments by harnessing the immune system's response to viral infections, potentially improving patient outcomes.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers develop resistance to conventional therapies, and new treatment options are needed to improve patient outcomes. Traditional cancer treatments can also harm healthy cells, leading to significant side effects.
Solution
KaliVir Immunotherapeutics is developing oncolytic viral immunotherapy programs that use its Novel Vaccinia Enhanced Template (VET) platform to selectively target and destroy cancer cells. The VET platform leverages a modified vaccinia virus to stimulate the immune system to recognize and attack tumors. This approach aims to provide a more targeted and effective cancer treatment while minimizing damage to healthy tissues.
Target Audience
The primary target audience includes patients with cancers that are resistant to conventional therapies, as well as oncologists and researchers seeking innovative treatment options.
Features
- Novel Vaccinia Enhanced Template (VET) platform for enhanced oncolytic activity
- Selective targeting of cancer cells to minimize off-target effects
- Stimulation of the immune system to recognize and eliminate tumors
- Potential for improved patient outcomes compared to traditional therapies